Crinetics (US.CRNX)
Capital Allocation Audit · Period: 2016 – 2026
Key Metrics
US.CRNX · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.7% | → |
| ROE | -10.0% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 0.04 | ↑ |
| Gross Margin | 98.1% | → |
US.CRNX (Crinetics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 100.7% → ROE -10.0% ↓ Cash Conversion - → D/E Ratio 0.04 ↑ Gross Margin 98.1% →
Key Metrics
US.CRNX (Crinetics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 100.7% →ROE -10.0% ↓Cash Conversion - →D/E Ratio 0.04 ↑Gross Margin 98.1% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies